Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
37.00    0.00 (0.00%)
Bid:
35.00
Ask:
39.00
Spread: 4.00 (11.429%)
Market Cap: £17.23m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

Investor Presentation

5 Oct 2020 07:00

RNS Number : 0252B
Cambridge Cognition Holdings PLC
05 October 2020
 

Cambridge Cognition Holdings plc

("Cambridge Cognition" or the "Company")

 

Investor Presentation

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that CEO Matthew Stork and CFO Nick Walters will provide a live investor presentation on Wednesday 14 October at 6.00pm London time.

 

The presentation is open to all existing and potential shareholders. Those wishing to attend should email zach.cohen@investor-focus.co.uk and they will be provided with log in details. There will be the opportunity for participants to ask questions at the end of the presentation. Questions can also be emailed to the above address ahead of the presentation.

 

Enquiries:

 

Cambridge Cognition Holdings plc

Tel: 01223 810 700

Matthew Stork, Chief Executive Officer

press@camcog.com

Nick Walters, Chief Financial Officer

finnCap Ltd (Nomad and Joint Broker)

Tel: 020 7220 0500

Geoff Nash/ Simon Hicks

(Corporate Finance)

Alice Lane/ Manasa Patil

(Corporate Broking)

Dowgate Capital Limited (Joint Broker)

Tel: 020 3903 7715

David Poutney/ James Serjeant

IFC Advisory Ltd (Financial PR and IR)

Tel: 020 3934 6630

Tim Metcalfe/ Graham Herring/ Zach Cohen

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAMIBPTMTAMBFM
Date   Source Headline
21st Sep 20217:00 amRNSInterim Results
3rd Aug 20217:00 amRNSTrading Update and Notice of Results
9th Jul 20214:41 pmRNSSecond Price Monitoring Extn
9th Jul 20214:35 pmRNSPrice Monitoring Extension
9th Jul 20217:00 amRNS£1 million contract for late phase cancer trial
1st Jul 20217:00 amRNSSpin-out of Monument Therapeutics
28th Jun 20214:40 pmRNSSecond Price Monitoring Extn
28th Jun 20214:36 pmRNSPrice Monitoring Extension
28th Jun 20212:06 pmRNSSecond Price Monitoring Extn
28th Jun 20212:00 pmRNSPrice Monitoring Extension
28th Jun 202111:05 amRNSSecond Price Monitoring Extn
28th Jun 202111:00 amRNSPrice Monitoring Extension
28th Jun 20217:00 amRNSNew £2.2 million contract
14th Jun 20217:00 amRNS£1.4m of contracts for digital health & wearables
11th Jun 20217:00 amRNSBrain Health Registry Cognitive Assessment Partner
3rd Jun 20213:58 pmRNSHolding(s) in Company
2nd Jun 20217:00 amRNSAppointment of Executive Director
27th May 202112:58 pmRNSResult of AGM and Board Changes
5th May 20217:00 amRNSPosting of Annual Report & Notice of AGM
4th May 202111:52 amRNSGrant of Options
8th Apr 20214:40 pmRNSSecond Price Monitoring Extn
8th Apr 20214:36 pmRNSPrice Monitoring Extension
8th Apr 20212:06 pmRNSSecond Price Monitoring Extn
8th Apr 20212:00 pmRNSPrice Monitoring Extension
8th Apr 202111:05 amRNSSecond Price Monitoring Extn
8th Apr 202111:00 amRNSPrice Monitoring Extension
8th Apr 20217:00 amRNSNew £0.5m contract for cognitive at home testing
30th Mar 20217:00 amRNS£1.3 million contract for a schizophrenia trial
23rd Mar 20217:00 amRNSResults for the year ended 31 December 2020
11th Mar 20217:00 amRNSInvestor Presentation
17th Feb 20216:20 pmRNSHolding(s) in Company
19th Jan 20216:03 pmRNSHolding(s) in Company
19th Jan 202111:06 amRNSSecond Price Monitoring Extn
19th Jan 202111:00 amRNSPrice Monitoring Extension
19th Jan 20217:00 amRNSTrading Update, Board Change & Notice of Results
21st Dec 20207:00 amRNSNew digital health contract worth over £700,000
2nd Dec 20201:10 pmRNSHolding(s) in Company
2nd Nov 20202:55 pmRNSGrant of Options
7th Oct 20207:00 amRNSNew £750,000 digital health contract
5th Oct 20207:00 amRNSInvestor Presentation
22nd Sep 20207:00 amRNSInterim Results
21st Sep 20203:13 pmRNSHolding(s) in Company
14th Sep 20207:00 amRNSAppointment of Non-Executive Director
8th Sep 20209:57 amRNSNotice of Results
7th Sep 202012:19 pmRNSHolding(s) in Company
1st Sep 20207:00 amRNS£2m contract for three schizophrenia trials
27th Jul 20201:11 pmRNSResult of AGM and Board Changes
15th Jul 20207:00 amRNSNew virtual study with COVID-19 healthcare workers
3rd Jul 20203:30 pmRNSPosting of Annual Report & Notice of AGM
30th Jun 20209:00 amRNSAnnual Report & Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.